Accelerate to discover

Back to filter

Related topics

Responsive fluorescence probe for detection of Hypochlorous acid in live cells and animals

Spectral Instruments Imaging

Jan 17, 2019

In this work, a new fluorescence probe, PQI, was developed for monitoring of the HOCl level in biological samples. The...

Improved differentiation of Retinal Organoids stem cells derived using rotating-wall vessels

Synthecon

Jan 15, 2019

Pluripotent stem cells can be differentiated into 3D retinal organoids, with major cell types self-patterning into a...

IncuCyte webinar recording: CAR T-cell therapy, frontiers in cancer Immunotherapy

Sartorius

Jan 11, 2019

The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of...

CT‐analyzer plug‐ins: ROI shrink‐wrap and primitive ROI

Bruker Biospin

Jan 7, 2019

The ROI shrink‐wrap gives the possibility to automatically generate a region‐of‐interest by adapting to the shape of...

Jan 23, 2019

ACEA Biosciences launch xCELLigence RTCA software Pro for immunotherapy applications

Acea Biosciences

Dec 28, 2018

RTCA Software Pro is an integrated software package for running and analyzing real time cell analysis data from...

Cellular stress induces erythrocyte assembly and promotes microangiopathy

Fluxion Biosciences

Dec 19, 2018

Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms...

The need for ultra high field magnetic resonance imaging

Bruker Biospin

Dec 17, 2018

MRI  is a noninvasive imaging technology that is known for its superior soft tissue contrast and ability to provide...

Jan 23, 2019

Live-cell labeling of endogenous proteins with nanometer precision by transduced nanobodies

Etaluma

Dec 6, 2018

Accurate labeling of endogenous proteins for advanced light microscopy in living cells remains challenging. Nanobodies...

Show all topics (10)

xCELLigence in personalized cancer medicine

Dec 8, 2016

The use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have already adapted to the liquid environment in the patient and do not depend on a stromal cell compartment. Aim of this study was to develop a systematic approach for the in-vitro culture of MPEs to analyze the effect of chemotherapeutic as well as targeted drugs.

Methods: MPEs from patients with solid tumors were selected for this study. After morphological and molecular characterization, they were cultured in medium supplemented with patient-derived sterile-filtered effusion supernatant. Growth characteristics were monitored in real-time using the xCELLigence system. MPEs were treated with a targeted therapeutic (erlotinib) according to the mutational status or chemotherapeutics based on the recommendation of the oncologists. Results: We have established a robust system for the ex-vivo culture of MPEs and the application of drug tests in-vitro. The use of an antibody based magnetic cell separation system for epithelial cells before culture allowed treatment of effusions with only moderate tumor cell proportion. Experiments using drugs and drug-combinations revealed dose-dependent and specific growth inhibitory effects of targeted drugs.

Conclusions: We developed a new approach for the ex-vivo culture of MPEs and the application of drug tests in-vitro using real-time measuring of cell growth, which precisely reproduced the effect of clinically established treatments by standard chemotherapy and targeted drugs. This sets the stage for future studies testing agents against specific targets from genomic profiling of metastatic tumor cells and multiple drug-combinations in a personalized manner.

Read more

Scientific paper
Application

Related technologies: Real-time, label free cell analysis

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The RTCA DP Analyzer has three integrated stations for E-Plates 16 or CIM-Plates 16

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on the E-Plate 96 to the RTCA Analyzer for impedance measurement

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on any of six E-Plates to the RTCA Analyzer for impedance measurement

show detail

Instrument can be integrated with automated liquid handling platforms or a robotic plate handler from different vendors

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey